CEO: David Lickrish
Year founded: 2008
Highland Therapeutics uses proprietary drug-delivery technology to develop improved versions of existing drug products. The company’s lead products, HLD-100 and HLD-200, are novel formulations of the stimulants commonly used to treat ADHD and seek to address a prevalent unmet medical need in the treatment of the disease: the lack of symptom control during the morning routine. Highland Therapeutics seeks to improve the lives of ADHD patients and their families by using today’s science to enhance yesterday’s treatments.
- News & Insights: Highland Therapeutics closes $25 million funding round
- News & Insights: Ontario startups that prove investing in biotech is worth the risk